BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

884 related articles for article (PubMed ID: 22178752)

  • 1. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.
    Millan MJ; Mannoury la Cour C; Chanrion B; Dupuis DS; Di Cara B; Audinot V; Cussac D; Newman-Tancredi A; Kamal M; Boutin JA; Jockers R; Marin P; Bockaert J; Muller O; Dekeyne A; Lavielle G
    J Pharmacol Exp Ther; 2012 Mar; 340(3):750-64. PubMed ID: 22178752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: II. A behavioral, neurochemical, and electrophysiological characterization.
    Dekeyne A; Brocco M; Loiseau F; Gobert A; Rivet JM; Di Cara B; Cremers TI; Flik G; Fone KC; Watson DJ; Papp M; Sharp T; Serres F; Cespuglio R; Olivier B; Chan JS; Lavielle G; Millan MJ
    J Pharmacol Exp Ther; 2012 Mar; 340(3):765-80. PubMed ID: 22178753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction.
    Chanrion B; Mannoury la Cour C; Gavarini S; Seimandi M; Vincent L; Pujol JF; Bockaert J; Marin P; Millan MJ
    Mol Pharmacol; 2008 Mar; 73(3):748-57. PubMed ID: 18083778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models.
    Dekeyne A; Mannoury la Cour C; Gobert A; Brocco M; Lejeune F; Serres F; Sharp T; Daszuta A; Soumier A; Papp M; Rivet JM; Flik G; Cremers TI; Muller O; Lavielle G; Millan MJ
    Psychopharmacology (Berl); 2008 Sep; 199(4):549-68. PubMed ID: 18523738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-HT(2C) receptor activation is a common mechanism on proerectile effects of apomorphine, oxytocin and melanotan-II in rats.
    Kimura Y; Naitou Y; Wanibuchi F; Yamaguchi T
    Eur J Pharmacol; 2008 Jul; 589(1-3):157-62. PubMed ID: 18582863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.
    Millan MJ; Newman-Tancredi A; Audinot V; Cussac D; Lejeune F; Nicolas JP; Cogé F; Galizzi JP; Boutin JA; Rivet JM; Dekeyne A; Gobert A
    Synapse; 2000 Feb; 35(2):79-95. PubMed ID: 10611634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine.
    Millan MJ; Dekeyne A; Newman-Tancredi A; Cussac D; Audinot V; Milligan G; Duqueyroix D; Girardon S; Mullot J; Boutin JA; Nicolas JP; Renouard-Try A; Lacoste JM; Cordi A
    J Pharmacol Exp Ther; 2000 Dec; 295(3):1192-205. PubMed ID: 11082457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.
    Newman-Tancredi A; Cussac D; Quentric Y; Touzard M; Verrièle L; Carpentier N; Millan MJ
    J Pharmacol Exp Ther; 2002 Nov; 303(2):815-22. PubMed ID: 12388668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ejaculatory response induced by a 5-HT2 receptor agonist m-CPP in rats: differential roles of 5-HT2 receptor subtypes.
    Yonezawa A; Yoshizumi M; Ebiko M; Ise SN; Watanabe C; Mizoguchi H; Kimura Y; Sakurada S
    Pharmacol Biochem Behav; 2008 Feb; 88(4):367-73. PubMed ID: 17936345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonin1A autoreceptor activation by S 15535 enhances circadian activity rhythms in hamsters: evaluation of potential interactions with serotonin2A and serotonin2C receptors.
    Gannon RL; Millan MJ
    Neuroscience; 2006; 137(1):287-99. PubMed ID: 16289351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
    Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G
    J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat.
    Gobert A; Rivet JM; Lejeune F; Newman-Tancredi A; Adhumeau-Auclair A; Nicolas JP; Cistarelli L; Melon C; Millan MJ
    Synapse; 2000 Jun; 36(3):205-21. PubMed ID: 10819900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
    Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A
    J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constitutive activity of serotonin 2C receptors at G protein-independent signaling: modulation by RNA editing and antidepressants.
    Labasque M; Meffre J; Carrat G; Becamel C; Bockaert J; Marin P
    Mol Pharmacol; 2010 Nov; 78(5):818-26. PubMed ID: 20699324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anxiolytic activity of a novel potent serotonin 5-HT2C receptor antagonist FR260010: a comparison with diazepam and buspirone.
    Harada K; Aota M; Inoue T; Matsuda R; Mihara T; Yamaji T; Ishibashi K; Matsuoka N
    Eur J Pharmacol; 2006 Dec; 553(1-3):171-84. PubMed ID: 17074317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile.
    Millan MJ; Gobert A; Newman-Tancredi A; Lejeune F; Cussac D; Rivet JM; Audinot V; Adhumeau A; Brocco M; Nicolas JP; Boutin JA; Despaux N; Peglion JL
    J Pharmacol Exp Ther; 2000 Jan; 292(1):38-53. PubMed ID: 10604930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity.
    Jensen NH; Rodriguiz RM; Caron MG; Wetsel WC; Rothman RB; Roth BL
    Neuropsychopharmacology; 2008 Sep; 33(10):2303-12. PubMed ID: 18059438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.
    Thomsen WJ; Grottick AJ; Menzaghi F; Reyes-Saldana H; Espitia S; Yuskin D; Whelan K; Martin M; Morgan M; Chen W; Al-Shamma H; Smith B; Chalmers D; Behan D
    J Pharmacol Exp Ther; 2008 May; 325(2):577-87. PubMed ID: 18252809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The bulky N6 substituent of cabergoline is responsible for agonism of this drug at 5-hydroxytryptamine 5-HT2A and 5-HT2B receptors and thus is a determinant of valvular heart disease.
    Kekewska A; Hübner H; Gmeiner P; Pertz HH
    J Pharmacol Exp Ther; 2011 Jul; 338(1):381-91. PubMed ID: 21518772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.